Evaluation of a Fourth-Generation Subcutaneous Real-Time Continuous Glucose Monitor (CGM) in Individuals With Diabetes on Peritoneal Dialysis.

"Duality of Interest. E.C. has received institutional research support and/or speaker fees from Bayer, Hua Medicine, Merck KGaA, Medtronic Diabetes, Power Pharmaceuticals, Inc., and Sanofi. A.O.Y.L. has served as a member of advisory panel for Amgen, AstraZeneca, Boehringer Ingelheim, and Sanofi and received research support from Amgen, Bayer, Boehringer Ingelheim, Lee’s Pharmaceutical, MSD, Novo Nordisk, Roche, Sanofi, Sugardown Ltd, and Takeda. None of these relationships had any influence on the content of the present manuscript. R.C.W.M. has received research funding from AstraZeneca, Bayer, Merck Sharp & Dohme, Novo Nordisk, Pfizer, and Tricida, Inc. for performing clinical trials and has received speaker honorarium or consultancy in advisory boards from AstraZeneca, Bayer, and Kyowa Kirin. J.C.N.C. has received research grants and/or honoraria for consultancy or giving lectures from Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Hua Medicine, Lee Powder, Merck Serono, Merck Sharp & Dohme, Pfizer, Servier, Sanofi, and Viatris Pharmaceutical. All proceeds have been donated to the Chinese University of Hong Kong to support diabetes research. No other potential conflicts of interest relevant to this article were reported."

"Funding. This study was supported by an investigator-initiated study grant under the Medtronic External Research Program ERP-2020-12226. A.O.Y.L. has received support from the Asia Diabetes Foundation. The authors acknowledge the support of the Health and Medical Research Fund Commisionned Program for Phase 1 Clinical Trial Centre (Novel Drugs-CUHK), the Food and Health Bureau, Hong Kong SAR."